Biology and software are converging faster than most organizations can track. Drug candidates get screened computationally before anyone touches a pipette. Clinical trials run on patient smartphones. Gene editors target conditions that had no treatment options a decade ago. This piece maps the life sciences technology trends that are actually gaining ground, what’s already in use, what’s still half-finished, and what problems none of this has solved yet.
Something Structural Has Changed
Growth in life sciences has held up through market volatility, rate hikes, and regulatory uncertainty, and there’s a reason for that. The sector stopped being purely about biology somewhere around 2020. By now, that shift is visible everywhere: R&D teams that once fought for lab space now argue over cloud compute budgets.
What’s behind it isn’t one breakthrough. It’s a stack, data infrastructure, AI tooling, genomics platforms, and the regulatory frameworks slowly catching up to all of them. Companies building that stack early are moving faster. For those still figuring out what specialized IT solutions for life sciences even look like in practice, the gap is getting harder to close. Not impossible, but harder.
And here’s the thing: the shift isn’t about adopting AI for its own sake. It’s about what happens when there’s finally enough clean, structured biological data to do something useful with it. That took years to build. The payoffs are starting to show.
AI in Drug Discovery: What “At Scale” Actually Looks Like
The Novartis Example
Novartis has been one of the more transparent companies about what AI-driven research looks like in practice. Their team working on ADPKD, autosomal dominant polycystic kidney disease, the most common inherited form of kidney failure, used large-scale AI simulations to toggle thousands of genes on and off in digital cell models, hunting for disease targets. In parallel, generative AI designed millions of potential compounds. The wet-lab team then synthesized roughly 60 of those.
In under a year, five targets were advancing to further study. That’s a published result from World Economic Forum briefings in early 2026, not a press release. And it illustrates something broader: AI isn’t replacing the bench, it’s deciding what gets to the bench in the first place.
Who’s Spending Real Money
The moves other major players made in 2026 tell a similar story:
- Eli Lilly opened TuneLab in late 2025, an AI platform trained on decades of proprietary data, now available to external biotech partners. Drug discovery infrastructure as a service, effectively
- Pfizer partnered with PostEra and Tempus for small-molecule development; their collaboration with Gero focused on patient population analysis and aging biology
- AstraZeneca signed a multi-billion partnership with CSPC to use an AI-driven drug discovery platform across chronic disease targets, binding pattern analysis, compound optimization, the whole pipeline
- Insilico Medicine got the most attention: their ISM001-055 compound for idiopathic pulmonary fibrosis became the first AI-designed small molecule to complete Phase IIa clinical trials
- Siemens acquired Dotmatics for north of $5 billion, a direct bet on AI-driven lab data management becoming standard infrastructure
Taken together, big pharma is buying data infrastructure and model capacity, not just molecules. That pattern isn’t random.
Digital Trends in Life Sciences: The Trial Design Shift
Ask anyone who’s managed a phase III clinical trial where time goes. Patient recruitment, almost every time. Decentralized Clinical Trials have been circling the industry for years, but they got serious traction as remote monitoring technology matured and the FDA warmed to hybrid models.
The basic idea: instead of requiring patients to visit a site every few weeks, data comes to the trial. Wearables, smartphone-based ePRO tools, remote nurse visits, all feeding into a central data platform. Less friction for patients. Broader geographic reach for sponsors.
Tools actually being used:
- Medidata Rave and Veeva Vault CTMS on the data management side
- Abbott’s FreeStyle Libre and iRhythm’s Zio patch for continuous metabolic and cardiac monitoring outside clinical settings
- AI-powered patient matching that works through electronic health records, faster and less biased than manual chart review
The digital trends in life sciences pointing toward decentralized design aren’t reversing. The FDA’s Real-World Evidence Program has been expanding what counts as acceptable evidence for drug approvals, EHR data, insurance claims, device outputs. The boundary between a trial and long-term monitoring is blurring.
Real-World Evidence: No Longer a Niche Argument
Real-world evidence used to be something companies raised cautiously in regulatory conversations. That’s changed. It’s now considered a legitimate supplement, sometimes a substitute, for traditional trial arms, particularly for rare diseases where placebo-controlled studies are difficult to run ethically.
The practical upshot: companies that built real-world data capabilities early now hold a regulatory asset that wasn’t on anyone’s roadmap five years ago.
Technology Trends in Life Sciences That Don’t Get Enough Attention
Regulatory Tech Is Getting a Software Upgrade
Regulatory submissions haven’t been fun in any decade. The volume of documentation required for a single approval, clinical study reports, manufacturing dossiers, pharmacovigilance filings, runs to tens of thousands of pages. Much of the process remains manual in ways that seem almost deliberately inefficient.
RegTech is the slow-moving but genuine answer. AI tools that flag inconsistencies in submission packages, automate literature review, draft responses to agency queries. The FDA published guidance in early 2025 on how it expects AI to be used in regulatory-facing workflows, focusing on traceability and risk documentation. The EU AI Act added another layer: from August 2025, AI systems used in high-stakes contexts need built-in audit trails and provenance records. Regulatory submissions qualify as high-stakes.
The technology trends in life sciences here aren’t glamorous. But companies treating compliance infrastructure as an engineering problem, not a legal department problem, are building something durable.
Supply Chains Finally Getting Serious
Cold chain logistics for biologics. Serialization for anti-counterfeiting. Demand forecasting that accounts for manufacturing lead times measured in months. These aren’t new problems. What’s new is that the tools to address them actually work now.
Active areas:
- Track-and-trace systems (legally required across the US, EU, and most of Asia-Pacific, still being implemented by companies that waited too long)
- IoT temperature monitoring for cell and gene therapy shipments, where a brief temperature excursion can destroy a batch worth hundreds of thousands of dollars
- AI demand models factoring in seasonal patterns, geopolitical disruptions, and raw material constraints as a single integrated system rather than separate spreadsheets
- Blockchain-based provenance for multi-partner manufacturing, where knowing exactly which facility touched which lot matters for recall management
The Talent Situation Is Not Getting Easier
Well. This is the part that doesn’t fit neatly into trend lists.
The tools described above need people who understand both the biology and the software, not two separate teams that occasionally meet, but people who can look at a model output and know whether it makes biological sense. That profile is rare and getting more expensive.
Across stalled AI initiatives the pattern is consistent enough to call it one of the quieter life sciences technology trends: models weren’t the problem. Data quality was. Integration was. The absence of anyone who could explain to a regulatory reviewer why the AI produced a particular result, that was the problem.
Companies making real progress have invested in cross-functional teams, clean data pipelines, and documentation practices that let them show their work. The ones still announcing AI partnerships without restructuring how their data is organized are, frankly, mostly generating press releases.
What’s Actually Coming Next
The technology trends in life sciences heading into the next few years aren’t speculative. Most are already in narrow deployment, waiting for infrastructure and regulation to catch up.
The digital trends in life sciences driving that next phase (agentic workflows, multimodal AI, digital biomarkers) aren’t ten-year horizons. Novartis screened millions of compounds computationally and brought sixty to the bench. Lilly turned proprietary AI models into shared infrastructure. Insilico ran an AI-designed molecule through Phase IIa.
These happened. The question for everyone else is whether the infrastructure exists to do something similar or whether the next few years get spent watching others move faster.
